Arndt Vogel· @ArndtVogel · X·· 2 days agoScore90
Body · original
Zanidatamab + CT ± tislelizumab for 1L HER2-positive mGEA: Second IA from HERIZON-GEA-01
#ESMO26 #ESMOAmbassadors
👉 mOS: 27 vs22.9 vs 19.6 mo
🧐Continued meaningful benefit for Zani & Tis independent of PDL-1
@myESMO @ASCO
812 views · 12 likes · 9 reposts · 0 replies
Conference abstracts
LBA79matched by Rapid oral 1: Gastrointestinal tumour, upper digestive
Zanidatamab (zani) + chemotherapy (CT) ± tislelizumab (TIS) for first-line (1L) HER2-positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (mGEA): Second interim analysis (IA) from HERIZON-GEA-01
https://esmocongress.esmo.orgSource: Arndt Vogel · x.com